RxDoctor Payments Data

Ralph Caselnova, MD

Cardiology · Amityville, NYNPI 1548219835

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 652 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 47 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. Among cardiology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,304in general payments, 2019–2025

Across 652 payments — averaging $25.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Johnson & Johnson$1K
  • Medtronic$1K
  • Inari Medical, Inc.$1K
  • Amgen$1K
  • Novartis$1K
  • plus $8K from 41 others

What the payments were for

  • Food & beverage$16,21799%
  • Education$871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,304 in reported general payments places this provider in the 90th percentile of 112 cardiology providers in New York.

See all cardiology providers in New York

Medicare billing

Part B allowed, 2024
$620,155
Medicare patients
1,165
Services billed
4,243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban206$252,681
OzempicSemaglutide167$200,217
EntrestoSacubitril/Valsartan132$199,956
XareltoRivaroxaban86$122,983
JardianceEmpagliflozin36$61,811
Repatha SureclickEvolocumab46$56,800
Droxidopa17$42,522
MounjaroTirzepatide21$25,989
FarxigaDapagliflozin Propanediol14$22,553
Praluent PenAlirocumab15$18,758
Nebivolol Hcl204$14,701
NexletolBempedoic Acid12$12,943
VascepaIcosapent Ethyl15$12,306
BrilintaTicagrelor12$8,466
LivaloPitavastatin Calcium12$7,594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$549$252,681206 claims
Novo NordiskOzempic$776$200,217167 claims
NovartisEntresto$1,053$199,956132 claims
Johnson & JohnsonXarelto$1,422$122,98386 claims
Boehringer IngelheimJardiance$427$61,81136 claims
AstraZenecaFarxiga, Brilinta$291$31,01926 claims
Lilly USA, LLCMounjaro$157$25,98921 claims
Esperion Therapeutics, Inc.Nexletol$484$12,94312 claims
Kowa Pharmaceuticals America, Inc.Livalo$122$7,59412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 112 cardiology providers in New York.

Other cardiology in Amityville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →